



## AFYREN announces the end of the stabilisation period, the partial exercise of the overallotment option and the implementation of a liquidity contract

- End of stabilization operations with partial exercise of the over-allotment option
- Total amount of the offering increased to EUR 70.4 million
- Implementation of a liquidity contract with NATIXIS ODDO BHF

Clermont-Ferrand/Lyon, 1<sup>st</sup> November 2021 - AFYREN, a greentech company that offers manufacturers natural and low-carbon products produced using a technology based on natural micro-organisms (ISIN code: FR- 0014005AC9 mnemonic: ALAFY), has received notification that Joh. Berenberg, Gossler & Co. KG (Kommanditgesellschaft) (limited partnership) (“Berenberg”), registered with the Commercial Register (Handelsregister) of the Local Court (Amtsgericht) of Hamburg under HRA 42659, acting as Stabilisation Manager in the context of the first admission to trading of ordinary shares of AFYREN on Euronext Growth Paris, has undertaken stabilization activities in relation to the first admission to trading on Euronext Growth Paris of the following securities:

Issuer:	AFYREN
Securities:	Ordinary shares with a par value of EUR 0.02. (ISIN: FR0014005AC9)
Offering Size:	8,286,359 ordinary shares (excluding the overallotment option)
Offer Price:	EUR 8.02 per ordinary share
Market:	Euronext Growth (Paris)
Stabilisation Manager:	Joh. Berenberg, Gossler & Co. KG (“Berenberg”)

## Notification of details of stabilisation transactions in accordance with Article 6 (2) DelReg (EU) 2016/1052

Pursuant to Article 6, paragraph 2, of Commission Delegated Regulation (EU) 2016/1052, AFYREN, on the basis of the information disclosed by Berenberg, hereby communicates that Berenberg has carried out, during the time period from 1 October 2021 until and including 29 October 2021, stabilisation measures as further specified below:

Execution Date	Intermediary	Stabilisation Trading Venue	Buy / Sell	Lowest price (in EUR)	Highest price (in EUR)	Weighted average price (in EUR)	Aggregate amount (in EUR)	Daily total of shares
01.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.3500	8.0200	7.7421	596,854.40	77,092
04.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.1400	7.8800	7.4878	112,256.79	14,992
05.10.2021	Berenberg	Euronext Growth (Paris)	Buy	6.9900	7.6300	7.2297	55,964.79	7,741
06.10.2021	Berenberg	Euronext Growth (Paris)	Buy	6.8200	7.5500	7.3845	205,325.36	27,805
07.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.1300	7.6000	7.5585	164,102.89	21,711
08.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.3600	7.6100	7.5788	113,500.81	14,976
11.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.5500	7.8000	7.7744	103,788.34	13,350
12.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.5000	7.9000	7.8725	118,575.12	15,062
13.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.7500	7.9400	7.9309	109,667.98	13,828
14.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.6800	7.9500	7.8775	113,341.62	14,388
15.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.7100	7.9800	7.9671	131,703.78	16,531
18.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.8300	7.9800	7.9720	110,555.90	13,868
19.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.8200	7.9800	7.9427	107,798.43	13,572
20.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.8200	8.0200	7.9958	115,859.40	14,490
21.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.9500	8.0200	8.0106	49,177.22	6,139
22.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.8500	8.0200	7.9828	16,723.99	2,095
25.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.9200	8.0200	7.9790	9,606.69	1,204
26.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.9400	8.0200	8.0103	29,758.09	3,715
27.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.9400	8.0200	8.0100	35,724.71	4,460
28.10.2021	Berenberg	Euronext Growth (Paris)	Buy	7.9900	8.0200	8.0164	9,395.27	1,172
29.10.2021	Berenberg	Euronext Growth (Paris)	Buy	8.0200	8.0200	8.0200	4,114.26	513

## Notification of the end of stabilization measures in accordance with Article 6 (3) DelReg (EU) 2016/1052

The stabilisation period, which began on 1 October 2021, ended on 30 October 2021. During this stabilisation period, stabilisation was carried out in respect of a total number of 298,704 shares in a price range between EUR 6.8200 (lowest price) and EUR 8.0200 (highest price) solely on Euronext Growth (Paris).

Further details regarding all stabilisation transactions carried out during the stabilisation period can be found on AFYREN's website dedicated to the IPO (<https://www.afyren-finance.com/>).

## Notification of the exercise of the partial exercise of the Greenshoe-Option in accordance with Article 8 lit. f) DelReg (EU) 2016/1052

In addition, on 30 October 2021, Berenberg acting as stabilizing agent, acting on its own and on behalf of the Joint Global Coordinators, exercised in part the over-allotment option to purchase 490,473 existing shares from the Selling Shareholders at the initial public offering price of €8.02 per share corresponding to a total amount of approximately €3.9 million.

As a result, the total number of AFYREN shares sold in its initial public offering amounts to 8,776,832 shares, including 8,286,359 new ordinary shares and 490,473 existing shares, bringing the total offering size to €70.4 million

After the exercise of the over-allotment option, AFYREN's public float amounts to 16.36% of its total share capital.

Following the offering and the exercise of the over-allotment option, AFYREN's share capital will be held as follows:

Shareholders <sup>1</sup>	After the Exercise of the Over-Allotment Option	
	Number of shares	% of share capital and voting rights
AFY Partners	4 412 425	17.13%
Nicolas Sordet	375 294	1.46%
Jérémy Pessiot	702 794	2.73%
Régis Nouaille	1 558 250	6.05%
Sofinnova Industrial Biotech I	3 313 273	12.86%
Hedgescope Ltd	2 879 950	11.18%
Sofimac Partners	1 219 415	4.73%
Other	3 263 544	12.67%
Mirova	2 164 802	8.40%
BPI	1 657 271	6.43%
Public	4 215 006	16.36%
<b>TOTAL</b>	<b>25 762 024</b>	<b>100.00%</b>

(1) On a non-diluted basis

This press release is issued also on behalf of Berenberg pursuant to Article 6, paragraph 2, of Commission Delegated Regulation (EU) 2016/1052.

## Implementation of a Liquidity Contract with NATIXIS ODDO BHF

AFYREN announces having appointed NATIXIS and ODDO BHF SCA to implement a liquidity contract, starting on 1st November 2021, for a period of one year tacitly renewable.

This contract complies with the decision of the Autorité des marchés financiers (AMF) n° 2021-01 of June, 22 2021 related to the establishing of liquidity contracts on shares as accepted market practice and the standard contract of the Association française des marchés financiers (AMAFI).

This contract with NATIXIS ODDO BHF aims at improving Company's shares trading on the regulated market of Euronext Paris.

The following resources have been allocated to the liquidity account:

- › 300,000 euros

The execution of the liquidity contract may be suspended upon occurrence of the following events or conditions:

- › when all conditions provided in Article 5 of the AMF Decision n° 2021-01 June 22, 2021 are met;
- › if the share is listed outside the thresholds authorized by the Company's Shareholders' Meeting;
- › upon the Company request.

The liquidity contract may be terminated at any time and without prior notice by AFYREN, at any time by NATIXIS and/or ODDO BHF SCA subject to fifteen (15) calendar days' notice.

### About AFYREN

To meet the growing need for manufacturers to address global warming and reduce the use of petroleum derivatives in their production chains, AFYREN produces biomolecules derived from the recycling of non-food biomass, widely used in the human and animal nutrition, flavours and fragrances, life sciences, material sciences and lubricant sectors. This renewable carbon production is part of a sound circular economy process achieved through the use of globally patented fermentation technologies developed on the basis of ten years of research. Founded in 2012 and managed by Nicolas Sordet and Jérémy Pessiot, AFYREN had 33 employees at its sites in Lyon, Clermont-Ferrand and Carling Saint-Avold at the end of December 2020. AFYREN is the winner of the 2030 Global Innovation Competition in the "Plant proteins and plant chemistry" category and was selected in the French Tech120 in January 2020 and 2021. In 2018, AFYREN embarked on the construction of its industrial-scale plant AFYREN NEOXY, which takes the form of a joint venture with the SPI fund for industrial projects companies managed by Bpifrance. AFYREN NEOXY will oversee the first industrial-scale production of AFYREN natural organic acids in the Grand Est region.

For more information: [afyren.com](https://afyren.com)

### Contacts

AFYREN  
Finance Department  
Maxime Cordonnier  
  
[investisseurs@afyren.com](mailto:investisseurs@afyren.com)

Investor Relations  
NewCap  
Theo Martin  
Tel: +331 44 71 94 94  
[afyren@newcap.eu](mailto:afyren@newcap.eu)

Media Relations  
NewCap  
Nicolas Merigeau  
Tel: +331 44 71 94 98  
[afyren@newcap.eu](mailto:afyren@newcap.eu)

Alter'Com Conseil  
Estelle Monraisse  
Tel: +331 60 41 81 52  
[estelle@altercom-conseil.fr](mailto:estelle@altercom-conseil.fr)

## Warning

This announcement does not, and shall not, in any circumstances constitute a public offering or an invitation to the public in connection with any offer in France, United Kingdom, United States, Canada, Australia, Japan or any other country.

No communication and no information in respect of this transaction or of AFYREN may be distributed to the public in any jurisdiction where a registration or approval is required.

This announcement is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and the Council of 14 June 2017 (the “Prospectus Regulation”). The prospectus approved by the AMF is available on the AMF website ([www.amf-france.org/](http://www.amf-france.org/)) and the company’s website dedicated to the IPO (<https://www.afyren-finance.com/>).

The distribution of this announcement is not made, and has not been approved, by an authorized person (“authorized person”) within the meaning of Article 21(1) of the Financial Services and Markets Act 2000. As a consequence, this announcement is directed only at persons who (i) are located outside the United Kingdom, (ii) have professional experience in matters relating to investments and fall within Article 19(5) (“investment professionals”) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) and (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons together being referred to as “Relevant Persons”). This announcement is not a prospectus which has been approved by the Financial Conduct Authority or any other United Kingdom regulatory authority for the purposes of Section 85 of the Financial Services and Markets Act 2000.

Securities may not be offered or sold in the United States unless they have been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or are exempt from registration. AFYREN does not intend to make a public offer of its shares in the United States.

The distribution of this document in certain countries may constitute a breach of applicable law. The information contained in this document does not constitute an offer of securities for sale in Canada, Australia or Japan. This announcement may not be published, forwarded or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.